<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE: Although <z:chebi fb="0" ids="2663">amiodarone</z:chebi> is recognized as the most effective anti-arrhythmic drug available, it has negative hemodynamic effects </plain></SENT>
<SENT sid="1" pm="."><plain>Nano-sized liposomes can accumulate in and selectively deliver drugs to ischemic/reperfused (I/R) myocardium, which may augment drug effects and reduce side effects </plain></SENT>
<SENT sid="2" pm="."><plain>We investigated the effects of liposomal <z:chebi fb="0" ids="2663">amiodarone</z:chebi> on lethal <z:hpo ids='HP_0011675'>arrhythmias</z:hpo> and hemodynamic parameters in an <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>/reperfusion rat model </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS AND RESULTS: We prepared liposomal <z:chebi fb="0" ids="2663">amiodarone</z:chebi> (mean diameter: 113 ± 8 nm) by a thin-film method </plain></SENT>
<SENT sid="4" pm="."><plain>The left coronary artery of experimental rats was occluded for 5 min followed by reperfusion </plain></SENT>
<SENT sid="5" pm="."><plain>Ex vivo fluorescent imaging revealed that intravenously administered fluorescent-labeled nano-sized beads accumulated in the I/R myocardium </plain></SENT>
<SENT sid="6" pm="."><plain><z:chebi fb="0" ids="2663">Amiodarone</z:chebi> was measurable in samples from the I/R myocardium when liposomal <z:chebi fb="0" ids="2663">amiodarone</z:chebi>, but not <z:chebi fb="0" ids="2663">amiodarone</z:chebi>, was administered </plain></SENT>
<SENT sid="7" pm="."><plain>Although the intravenous administration of <z:chebi fb="0" ids="2663">amiodarone</z:chebi> (3 mg/kg) or liposomal <z:chebi fb="0" ids="2663">amiodarone</z:chebi> (3 mg/kg) <z:mp ids='MP_0005333'>reduced heart rate</z:mp> and systolic blood pressure compared with saline, the decrease in heart rate or systolic blood pressure caused by liposomal <z:chebi fb="0" ids="2663">amiodarone</z:chebi> was smaller compared with a corresponding dose of free <z:chebi fb="0" ids="2663">amiodarone</z:chebi> </plain></SENT>
<SENT sid="8" pm="."><plain>The intravenous administration of liposomal <z:chebi fb="0" ids="2663">amiodarone</z:chebi> (3 mg/kg), but not free <z:chebi fb="0" ids="2663">amiodarone</z:chebi> (3 mg/kg), 5 min before <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> showed a significantly reduced duration of lethal <z:hpo ids='HP_0011675'>arrhythmias</z:hpo> (18 ± 9 s) and mortality (0 %) during the reperfusion period compared with saline (195 ± 42 s, 71 %, respectively) </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS: Targeting the delivery of liposomal <z:chebi fb="0" ids="2663">amiodarone</z:chebi> to ischemic/reperfused myocardium reduces the mortality due to lethal <z:hpo ids='HP_0011675'>arrhythmia</z:hpo> and the negative hemodynamic changes caused by <z:chebi fb="0" ids="2663">amiodarone</z:chebi> </plain></SENT>
<SENT sid="10" pm="."><plain>Nano-size liposomes may be a promising drug delivery system for targeting I/R myocardium with cardioprotective agents </plain></SENT>
</text></document>